CARES-1 is a randomised, open-label, phase II pharmacokinetic (PK) and safety study of ambulatory antibiotics for the treatment of neonates with "all-risk" asymptomatic congenital syphilis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Time above MIC in serum
Timeframe: From enrolment through to day 10 of the study
Time above MIC in CSF
Timeframe: 10 days
Adverse Events
Timeframe: Assessed from enrolment through to 24 weeks